# Roche Initiates Phase II TARBELA-AD Trial of Oral RG6434 and Presents 16 Alzheimer's Abstracts at CTAD 2026

> Roche is initiating a Phase II trial of oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease and presenting 16 abstracts at CTAD 2026 in Boston.

- Published: 2026-11-10T06:22:07+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-10/roche-phase-two-tarbela-ad-rg6434
- Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/10/3399142/0/en/roche-presents-new-data-across-pharmaceuticals-and-diagnostics-from-its-growing-alzheimer-s-disease-portfolio-at-ctad-2026.html)

## Key takeaways

- Roche is initiating the Phase II TARBELA-AD trial of the investigational oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease.
- Roche will present 16 accepted abstracts at the 19th CTAD Congress in Boston from November 16 to 19, 2026.
- The Phase III PrevenTRON study of trontinemab in preclinical Alzheimer's disease has started enrolling participants.

[Roche](https://akta.pro/company-profiles/00000om/roche) is initiating a Phase II clinical trial, TARBELA-AD, evaluating the investigational oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease, the company said on November 10, 2026. The Swiss pharmaceutical and diagnostics group announced the move alongside new data across its Alzheimer's portfolio at the 19th Clinical Trials on Alzheimer's Disease Congress, according to [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/10/3399142/0/en/roche-presents-new-data-across-pharmaceuticals-and-diagnostics-from-its-growing-alzheimer-s-disease-portfolio-at-ctad-2026.html).

## Roche's TARBELA-AD Trial and CTAD Presentations

Roche said it will present data across its pharmaceuticals and diagnostics portfolios at CTAD 2026, taking place in Boston from November 16 to 19, 2026, across 16 accepted abstracts, including two scientific symposia and two oral presentations. The TARBELA-AD study is a Phase II, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of RG6434 in early symptomatic Alzheimer's disease, and its rationale and design will be shown in a poster at the congress.

"Amyloid clearance remains a vital foundation, but halting a disease as complex as Alzheimer's demands multifaceted and complementary strategies," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development. "By advancing our Phase II TARBELA-AD trial evaluating an NLRP3 inhibitor, alongside ongoing trontinemab programmes, we will test additional therapeutic hypotheses to potentially stop or prevent disease progression."

Updated Phase Ib/IIa Brainshuttle AD study data for trontinemab will be presented in a symposium on November 16, covering neuroimaging, pharmacokinetics and pharmacodynamics, and safety data. An oral presentation on November 18 will detail the design and participant screening of the Phase III PrevenTRON study of trontinemab in preclinical Alzheimer's disease, which has commenced enrolment. Geoff Kerchner, Global Head of Neurodegeneration Product Development at Roche, will give a keynote address on November 17.

## Roche's Diagnostics Data at CTAD

Roche's diagnostics division will present clinical, health economic and real-world data for its Elecsys pTau217 and Elecsys pTau181 blood tests across multiple posters available from November 16. Matt Sause, CEO of Roche Diagnostics, said: "Elecsys pTau217 is the first and only FDA-cleared, single biomarker blood test that both rules in and rules out amyloid pathology." Roche said key presentations will explore the impact of integrating blood-based pTau217 testing into routine clinical practice on healthcare economics and efficiency of diagnostic pathways.

## Roche's Alzheimer's Pipeline Background

Roche, founded in Basel in 1896, develops prescription medicines and companion diagnostic tests across oncology, neurology, immunology, ophthalmology and infectious diseases, according to akta.pro [company records](https://akta.pro/company-data). The company's Alzheimer's portfolio spans investigational medicines targeting complementary biological pathways, from amyloid to neuroinflammation, with candidates including trontinemab, nivegacetor and RG6434, and its diagnostics division offers approved cerebrospinal fluid assays and blood-based tests including Elecsys pTau181, Elecsys pTau217 and ApoE4.

## What Comes Next for Roche's Alzheimer's Programmes

Roche said abstracts will be available on the CTAD website. The congress runs from November 16 to 19, 2026, with the trontinemab symposium on November 16, the RG6434 neuroinflammation symposium and Kerchner keynote on November 17, and the PrevenTRON oral presentation on November 18.

## Companies in this story

- [Roche company profile](https://akta.pro/company-profiles/00000om/roche) · website: http://www.roche.com

---
News for Agent · https://newsforagent.com/llms.txt